Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
Canales
Miguel A
MA
Martin
Alejandro
A
Caballero
Dolores
D
Hernandez-Navarro
Fernando
F
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005047:Etoposide / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D012008:Recurrence; D016879:Salvage Therapy
D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine